Holen Sie sich die Stockscreener-App
6.33
3.09%
0.19
Vorhandelsmarkt:
6.36
0.03
+0.47%
Schlusskurs vom Vortag:
$6.14
Offen:
$6.3
24-Stunden-Volumen:
2.02M
Relative Volume:
1.08
Marktkapitalisierung:
$556.05M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-209.47M
KGV:
-1.9021
EPS:
-3.3279
Netto-Cashflow:
$-147.13M
1W Leistung:
+16.15%
1M Leistung:
+13.04%
6M Leistung:
-32.66%
1J Leistung:
+31.60%
1-Tages-Spanne:
$6.215
$6.5789
1-Wochen-Bereich:
$5.23
$6.5789
52-Wochen-Spanne:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.33 | 539.36M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-02-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
PI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, - openPR.com
Chipmakers Recap: How is Verastem Inc managing supply chain issues2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Aug Wrap: What analysts say about Verastem Inc stock2026 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com - Investing.com Canada
Sentiment Recap: What analysts say about Verastem Inc stockTrade Entry Report & AI Optimized Trade Strategies - baoquankhu1.vn
Verastem Oncology’s combo shows two-year durability in ovarian cancer - MSN
Fed Meeting: What is the Moat Score of Verastem IncQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn
Today's Analyst Rating Data for VSTM: Maintained Buy Rating | VS - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 | VSTM Stock News - GuruFocus
Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 - GuruFocus
Verastem stock maintains Buy rating at BTIG on durable trial data - Investing.com Canada
Verastem (VSTM) Presents Positive Two-Year Data for Ovarian Canc - GuruFocus
Verastem’s cancer drug combo shows durability in 2-year data By Investing.com - Investing.com India
Verastem’s cancer drug combo shows durability in 2-year data - Investing.com
Verastem Oncology announces two-year median follow-up data on Avmapki® Fakzynja® combination therapy - marketscreener.com
Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy - TradingView — Track All Markets
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s C - Business Wire
Weekly Trades: What analysts say about Verastem Inc stockCEO Change & Weekly High Potential Alerts - baoquankhu1.vn
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Verastem (Nasdaq: VSTM) boosts equity and ESPP share pools for employees - Stock Titan
Understanding Momentum Shifts in (VSTM) - Stock Traders Daily
Working capital per share of Verastem, Inc. – MUN:2VSA - TradingView — Track All Markets
VSTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance UK
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com
Alison Lawton and Michael Kauffman Join Verastem Board of Directors - Yahoo
Verastem, Inc. (2VSA.F) stock price, news, quote and history - Yahoo Finance Singapore
Verastem Oncology announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Stephen Sherwin, M.D., Joins Verastem Board of Directors - yahoo.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com
Verastem (VSTM): Jefferies Lowers Price Target but Retains 'Buy' Rating | VSTM Stock News - GuruFocus
Verastem's (VSTM) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15 - Moomoo
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Jefferies lowers Verastem stock price target on valuation refresh - Investing.com UK
Jefferies lowers Verastem stock price target on valuation refresh By Investing.com - Investing.com India
Vanguard disaggregates holdings; reports 0 shares of Verastem (NASDAQ: VSTM) - Stock Titan
Cancer Stocks Worth Considering as Breakthroughs Transform the Worldwide Oncology Industry - Bitget
Verastem (VSTM) CFO receives 57-share stock award in Form 4 - stocktitan.net
Market Moves: What analysts say about Verastem Inc stock2026 Earnings Surprises & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha
Verastem Oncology drops despite Q3 double beat - MSN
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union
FinancialContentVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - FinancialContent
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):